@article {Mandalae001694, author = {Mario Mandala and Paul Lorigan and Matilde De Luca and Andrea Bianchetti and Barbara Merelli and Anna Cecilia Bettini and Lucia Bonomi and Sharon Nahm and Maria Grazia Vitale and Giorgia Negrini and Andrea Di Croce and Paolo Antonio Ascierto and Eliana Rulli and Carlo Alberto Tondini}, title = {SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study}, volume = {9}, number = {2}, elocation-id = {e001694}, year = {2021}, doi = {10.1136/jitc-2020-001694}, publisher = {BMJ Specialist Journals}, abstract = {Background In ambulatory patients with cancer with asymptomatic or pauci-symptomatic SARS-CoV-2 infection, the safety of targeted therapies (TTs), chemotherapy (CT) or immune checkpoint inhibitors (ICIs) therapy is still unknown.Material and methods From the start of the first epidemic wave of SARS-CoV-2 in Bergamo, Italy, we have prospectively screened all consecutive outpatients who presented for treatment to the Oncology Division of the Papa Giovanni XXIII Hospital, Bergamo for SARS-CoV-2 antigen expression. We identified patients treated with ICIs and compared these to patients with the same cancer subtypes treated with TTs or CT.Results Between March 5 and May 18, 293 consecutive patients (49\% melanoma, 34\% non-small cell lung cancer, 9\% renal cell carcinoma, 8\% other) were included in this study: 159 (54\%), 50 (17\%) and 84 (29\%) received ICIs, CT or TTs, respectively. Overall 89 patients (30.0\%) were SARS-CoV-2 positive. Mortality of SARS-CoV-2-positive patients was statistically significantly higher compared with SARS-CoV-2 negative patients (8/89 vs 3/204, respectively, Fisher{\textquoteright}s exact test p=0.004). All deaths were due to COVID-19. Serious adverse events (SAEs) were more frequent in SARS-CoV-2-positive patients compared with SARS-CoV-2-negative cases (Cochran-Mantel-Haenszel (CMH) test p=0.0008). The incidence of SAEs in SARS-CoV-2 positive compared with SARS-CoV-2 negative patients was similar in ICI and CT patients (17.3\% and 3.7\% for positive and negative patients in ICIs and 15.4\% and 2.7\% in CT, Breslow-Day test p=0.891). No COVID-19-related SAEs were observed in the TTs patients.Conclusions The incidence of SAEs was higher for SARS-CoV-2-positive patients treated with ICIs and CT, mostly in advanced disease. No SAEs were observed in patients treated with TTs. SAEs were COVID-19 related rather than treatment related. Treatment with ICIs does not appear to significantly increase risk of SAEs compared with CT. This information should be considered when determining treatment options for patients.All data relevant to the study are included in the article or uploaded as supplementary information. Additional data are available upon resonable request.}, URL = {https://jitc.bmj.com/content/9/2/e001694}, eprint = {https://jitc.bmj.com/content/9/2/e001694.full.pdf}, journal = {Journal for ImmunoTherapy of Cancer} }